Evofem Biosciences (EVFM) Proxy Filing summary

Executive summary

• The proxy filing details a proposed merger between Evofem Biosciences, Inc. and Aditxt, Inc., with Evofem becoming a wholly owned subsidiary of Aditxt upon closing, expected in the second half of 2025, subject to shareholder and regulatory approvals.

• Evofem shareholders will vote on the merger and an adjournment proposal at a special meeting scheduled for September 26, 2025.

• The merger consideration includes $1.8 million in cash for common shareholders and a one-for-one exchange of Series E-1 and Series G-1 preferred shares for Aditxt Series A-2 Preferred Stock.

• The transaction is structured to provide a premium to Evofem's recent trading price and is supported by a series of equity investments from Aditxt into Evofem prior to closing.

• The merger agreement has been amended multiple times to adjust investment schedules, closing conditions, and to include new classes of preferred stock.

Voting matters and shareholder proposals

• Shareholders are asked to approve the merger agreement and the adjournment of the special meeting if more time is needed to solicit votes.

• Approval requires a majority of the combined voting power of common and preferred shares, with additional majority approval needed from each preferred series.

• Dissenting shareholders have appraisal rights under Delaware law, subject to strict procedural requirements.

• Support agreements have been signed with key investors to vote in favor of the merger and restrict transfers of their shares until closing or termination.

Board of directors and corporate governance

• The current Evofem board consists of experienced professionals in life sciences, finance, and regulatory affairs.

• After the merger, the surviving company’s officers will be Saundra Pelletier (CEO) and Ivy Zhang (CFO), with directors including Pelletier, Amro Albanna, and Lisa Rarick.

• The board recommends voting in favor of the merger and adjournment proposals.